Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
about
Physiologically based pharmacokinetic modeling and simulation in pediatric drug developmentA physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsApplication of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in AdultsTreating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective.Prediction of drug clearance in children: a review of different methodologies.Neonatal medicines research: challenges and opportunities.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study.Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants.Allometry Is a Reasonable Choice in Pediatric Drug Development.
P2860
Q34658074-E724256E-D69B-439F-A828-EF5CB7E3FE90Q36025902-BA3DF56C-1BA0-4234-A0DC-6B12B2B46D36Q36159334-164FDC44-E633-4B52-94BD-2001E11FF3AEQ36410220-73F28D90-EE12-46E5-B512-3011F093DC3FQ37283027-8B57B449-0A53-420A-97BF-0862CFC5AEC8Q38245572-E0267276-5A94-43AF-AFBF-D4A326302475Q38367747-E3D3B6A5-9A59-41A5-885C-6F4D03482DFDQ38469763-207DE25D-9D98-4B0B-B16C-6DF294D38294Q38527434-B4DB2BEE-FE46-47B5-9408-05BB7CB6382DQ38959281-1A90EF42-9A48-43BB-9ECD-FCEEFED83203Q39676474-10C91D0E-7AD8-4B14-AB18-9613BAEB06D6Q43456116-617075EC-4A42-4323-9433-18C566B6CD21Q46018689-E00ABA72-BA64-4358-87BF-F00988170BFCQ48076685-32BC76B2-FCF9-4CFC-884F-6BC4E535A8A0Q54771792-EA246138-2C3B-43C9-A95C-A96E79617E51
P2860
Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Physiologically based pharmaco ...... range-sotalol as a model drug.
@en
type
label
Physiologically based pharmaco ...... range-sotalol as a model drug.
@en
prefLabel
Physiologically based pharmaco ...... range-sotalol as a model drug.
@en
P2860
P1433
P1476
Physiologically based pharmaco ...... range-sotalol as a model drug.
@en
P2093
Feras Khalil
Stephanie Läer
P2860
P2888
P304
P356
10.1208/S12248-013-9555-6
P407
P577
2014-01-08T00:00:00Z
P5875
P6179
1029878155